- Stocks
- Pharma & Healthcare
- Maestros Elect
Maestros Elect share price
NSE: METSLPharma & HealthcareMedical Devices
Maestros Elect at a glance
With a market capitalisation of ₹76 Cr, it ranks 2815th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.
Its return on equity was 17.2% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹12 Cr (+51.3% year on year) and net profit ₹2 Cr (+173.3%), on a consolidated basis. Promoters held 63.90% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹76 CrRank 2815 on NSE
- Price to book
- 1.57×FY26
- EPS (TTM)
- ₹13.16to Q4 FY26
- ROE
- 17.2%FY26
- ROCE
- 19.6%FY26
- Debt to equity
- 0.04FY26
- Net profit margin
- 18.4%FY26
- Book value / share
- ₹76.51FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Maestros Elect quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹9 Cr | ₹7 Cr | ₹5 Cr | ₹8 Cr | ₹10 Cr | ₹6 Cr | ₹11 Cr | ₹12 Cr |
| Revenue YoY | — | — | +49.6% | — | +19.9% | −19.4% | +123.0% | +51.3% |
| Net profit | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹3 Cr | ₹2 Cr |
| Net profit YoY | — | — | +284.2% | — | −14.0% | −34.7% | +272.6% | +173.3% |
| Net margin | 20.5% | 13.8% | 14.6% | 10.9% | 14.7% | 11.2% | 24.4% | 19.7% |
| EPS | ₹3.23 | ₹1.83 | ₹1.32 | ₹1.56 | ₹2.78 | ₹1.19 | ₹4.93 | ₹4.26 |
Maestros Elect financials
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹33 Cr | ₹29 Cr | — |
| Operating profit | ₹7 Cr | ₹6 Cr | — |
| Net profit | ₹5 Cr | ₹4 Cr | — |
| EPS (₹) | ₹9.00 | ₹8.00 | — |
| Cash from operations | ₹7 Cr | ₹6 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹31 Cr | ₹35 Cr | ₹42 Cr |
Maestros Elect shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 55.62% | 55.66% | 60.20% | 60.22% | 60.22% | 63.90% |
| Foreign institutions | 0.20% | 0.20% | 0.20% | 0.20% | 0.20% | 0.20% |
| Non-institutions | 44.17% | 44.14% | 39.60% | 39.57% | 39.57% | 35.90% |
Maestros Elect vs peers
The listed Pharma & Healthcare companies nearest to Maestros Elect by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AMWILLAmwill Health | — | — | — | ₹89 Cr | — | — |
| MDRCModern Diagnost | — | — | — | ₹81 Cr | — | — |
| METSLMaestros Elect | — | — | — | ₹76 Cr | — | — |
| BIBCLBharat Immuno | — | — | — | ₹75 Cr | — | — |
| SOURCENTRLSource Natural | — | — | — | ₹70 Cr | — | — |
| APLAsston Pharma | — | — | — | ₹69 Cr | — | — |
| FERVENTSYNFervent Synergi | — | — | — | ₹68 Cr | — | — |
Ask anything about Maestros Elect
Pivot answers on the live chart with evidence you can check, and tests strategies against METSL's own history. Try: “Why has METSL moved over the last three months?” · “Backtest a 50-day moving-average crossover on METSL over five years” · “Compare METSL with AMWILL on margins and valuation”
Frequently asked questions about Maestros Elect
What is the market cap of Maestros Elect?
Maestros Elect's market capitalisation is ₹76 Cr (₹76 Cr) at the 22 Oct 2026 close, ranking 2815th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Maestros Elect?
Return on equity was 17.2% in FY26 and return on capital employed was 19.6% in FY26 (consolidated figures).
Is Maestros Elect a debt-free company?
Maestros Elect is close to debt-free: its debt-to-equity ratio was 0.04 in FY26.
What were Maestros Elect's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Maestros Elect reported revenue of ₹12 Cr, +51.3% year on year, and net profit of ₹2 Cr, +173.3% year on year.
What is the shareholding pattern of Maestros Elect?
As of 30 Jun 2026: promoters 63.90%, foreign institutions 0.20%, non-institutions 35.90%.
Who are Maestros Elect's competitors?
The listed Pharma & Healthcare companies closest to Maestros Elect by market cap are Amwill Health, Modern Diagnost, Bharat Immuno, Source Natural, Asston Pharma and Fervent Synergi.
Is Maestros Elect a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Maestros Elect's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on METSL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text